# Re-evaluation Task: HN3-002

## Context
- **Case ID**: HN3-002
- **Cancer type**: Lower alveolar ridge (mandibular gingival) squamous cell carcinoma
- **Stage**: T3N1M0 (Stage III) — cortical mandibular invasion
- **Molecular profile**: PD-L1 CPS 15, CDKN2A loss (p16-negative, HPV-unrelated), 45-year-old male, active smoker, Cortical bone invasion without medullary extension
- **Report file**: experiment_reports\HN3-002_report.json
- **Current score**: 86/100
- **Gap analysis (local GPU)**: The most critical gaps in the HN3-002 cancer research report are the lack of data on Pembrolizumab + Marginal Mandibulectomy + Free Fibula Flap + Neck and Adjuvant Cisplatin-Based Chemoradiation, as these combinations are crucial for understanding the efficacy of immunotherapy and chemotherapy in treating head and neck cancers. Filling these gaps will improve the score by providing more comprehensive insights into treatment outcomes, allowing researchers to make more informed decisions about patient care and potentially leading to improved survival rates and quality of life for patients with head and neck cancer.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  13/25  |  52.0% |
| clinical_relevance                  |   9/10  |  90.0% |
| rating_calibration                  |  14/15  |  93.3% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (52.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\HN3-002_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Lower alveolar ridge (mandibular gingival) squamous cell carcinoma",
    "stage": "T3N1M0 (Stage III) — cortical mandibular invasion",
    "molecular_profile": [
      "PD-L1 CPS 15",
      "CDKN2A loss (p16-negative, HPV-unrelated)",
      "45-year-old male, active smoker",
      "Cortical bone invasion without medullary extension"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Perioperative Pembrolizumab + Marginal Mandibulectomy + Adjuvant CRT (KEYNOTE-689 Regimen)",
      "category": "Immunotherapy",
      "composite_rating": 8.1,
      "rating_breakdown": {
        "evidence_level": {
          "score": 9,
          "rationale": "Phase 3 RCT (KEYNOTE-689, N=714) published in NEJM 2025. Median EFS 51.8 vs 30.4 months (HR 0.73, p=0.008). FDA approved June 2025 for perioperative use in PD-L1 CPS>=1 LA-HNSCC. First positive perioperative immunotherapy trial in HNSCC. Oral cavity was an eligible subsite."
        },
        "survival_benefit": {
          "score": 8,
          "rationale": "Median EFS improvement of 21.4 months (51.8 vs 30.4 months). 36-month DMFS 59.1% vs 49.9% (HR 0.71). The patient's PD-L1 CPS 15 exceeds the CPS>=1 threshold, placing him in a favorable response subgroup. OS data maturing with positive trend."
        },
        "accessibility": {
          "score": 8,
          "rationale": "FDA approved June 2025 for PD-L1+ resectable LA-HNSCC. Pembrolizumab widely available at most cancer centers. Patient's CPS 15 meets eligibility. Requires coordination of 2 neoadjuvant cycles before definitive surgery."
        },
        "safety_profile": {
          "score": 6,
          "rationale": "Grade>=3 AEs 44.6% vs 42.9% (modest increment). Neoadjuvant pembro did not impair surgical completion rates. Immune-related AEs (thyroiditis 8-12%, colitis 2-5%, hepatitis 1-3%) are manageable. Added to baseline surgical + CRT toxicity burden."
        },
        "biomarker_match": {
          "score": 9,
          "rationale": "Patient's PD-L1 CPS 15 well exceeds the CPS>=1 threshold for FDA-approved indication. In KEYNOTE-048, CPS>=20 showed greatest benefit; CPS 15 is in the favorable range. CPS>=1 subgroup HR 0.70 (95% CI 0.55-0.89, p=0.003) in KEYNOTE-689."
        }
      },
      "mechanism_of_action": "Neoadjuvant pembrolizumab (2 cycles, 200 mg IV q3w) blocks PD-1/PD-L1 interaction to prime antitumor T-cell response before surgery, potentially converting immunologically cold tumors to hot and enabling immune recognition of micrometastatic disease. Following marginal mandibulectomy with free fibula flap reconstruction and neck dissection, adjuvant pembrolizumab (up to 15 cycles) maintains immune surveillance. Combined with risk-adapted adjuvant RT +/- cisplatin.",
      "key_evidence": {
        "study_name": "KEYNOTE-689",
        "journal": "New England Journal of Medicine",
        "year": 2025,
        "sample_size": 714,
       
... (truncated — read full file from experiment_reports\HN3-002_report.json)
```
